Robert Zeldin

Robert Zeldin

Chief Tech/Sci/R&D Officer at MEIRAGTX HOLDINGS PLC

Net worth: 553 597 $ as of 2024-02-28

61 year
Health Technology
Consumer Services
Commercial Services

Profile

Robert K.
Zeldin
occupies the position of Chief Medical Officer for MeiraGTx Holdings Plc.
He previously was Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc., Senior Vice President-Global Clinical Development at Stallergenes SA, Chief Medical Officer at Ablynx NV, Medical Officer at Center for Biologics Evaluation & Research, Chief Medical Officer of Immunovant, Inc. and Vice President at Novartis Pharmaceuticals Corp.
He received a doctorate from Tufts University School of Medicine and an undergraduate degree from The Johns Hopkins University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-01-16 89,724 ( 0.14% ) 553 597 $ 2024-02-28

Robert Zeldin active positions

CompaniesPositionStart
MEIRAGTX HOLDINGS PLC Chief Tech/Sci/R&D Officer 2020-08-04
All active positions of Robert Zeldin

Former positions of Robert Zeldin

CompaniesPositionEnd
ACCELERON PHARMA INC. Chief Tech/Sci/R&D Officer 2019-04-04
STALLERGENES Chief Tech/Sci/R&D Officer 2014-12-31
IMMUNOVANT, INC. Chief Tech/Sci/R&D Officer -
Corporate Officer/Principal -
Chief Tech/Sci/R&D Officer -
See the detail of Robert Zeldin's experience

Training of Robert Zeldin

The Johns Hopkins University Undergraduate Degree
Tufts University School of Medicine Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Zeldin's experience

Connections

31

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
IMMUNOVANT, INC.

Health Technology

Private companies6

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

MeiraGTx Holdings Plc

See company connections
  1. Stock
  2. Insiders
  3. Robert Zeldin